EcoDrugPlus

Lysyl Oxidase Homolog 2a-Like

Ensembl ID : ENSSTUG00000007564
Gene Symbol: LOC115150385
3 Cross references
204 Possible Orthologues:

Lysyl Oxidase Homolog 2b

Ensembl ID : ENSSTUG00000002637
Gene Symbol: LOC115200385
3 Cross references
206 Possible Orthologues:

Lysyl Oxidase Homolog 2b-Like

Ensembl ID : ENSSTUG00000014246
Gene Symbol: LOC115164266
3 Cross references
206 Possible Orthologues:

Macrophage Colony-Stimulating Factor 1 Receptor 1-Like

Ensembl ID : ENSSTUG00000003249
Gene Symbol: LOC115205390
2 Cross references
58 Possible Orthologues:

Macrophage Colony-Stimulating Factor 1 Receptor 1-Like

Ensembl ID : ENSSTUG00000024980
Gene Symbol: LOC115204516
2 Cross references
200 Possible Orthologues:

Macrophage Migration Inhibitory Factor

Ensembl ID : ENSSTUG00000006412
Gene Symbol: MIF
1 Cross references
160 Possible Orthologues:

Macrophage Migration Inhibitory Factor-Like

Ensembl ID : ENSSTUG00000002437
Gene Symbol: LOC115205374
3 Cross references
221 Possible Orthologues:

Macrophage Migration Inhibitory Factor-Like

Ensembl ID : ENSSTUG00000006423
Gene Symbol: LOC115174008
3 Cross references
221 Possible Orthologues:

Macrophage Stimulating 1 Receptor

Ensembl ID : ENSSTUG00000016269
Gene Symbol: MST1R
3 Cross references
181 Possible Orthologues:

Macrophage Stimulating 1 Receptor

Ensembl ID : ENSSTUG00000021960
Gene Symbol: MST1R
1 Cross references
181 Possible Orthologues:

Macrophage-Stimulating Protein Receptor-Like

Ensembl ID : ENSSTUG00000016484
Gene Symbol: LOC115207569
2 Cross references
187 Possible Orthologues:

Macrophage-Stimulating Protein Receptor-Like

Ensembl ID : ENSSTUG00000035987
Gene Symbol: LOC115150855
2 Cross references
187 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).